Blast crisis

Blast crisis may be discovered incidentally on complete blood count or when assessing patients with symptoms and signs such as fever, fatigue, malaise, weight loss, anemia, thrombocytopenia, or splenomegaly.

Complete blood count with differential is the initial laboratory test. Cytopenias and the presence of blast cells serve as clues to diagnosis. These should lead to a peripheral blood smear and bone marrow examination.

Diagnosis is usually confirmed by the percentage of blast cells (e.g., ≥20% [World Health Organization criteria] or ≥30% [MD Anderson Cancer Center and the International Bone Marrow Transplant Registry criteria]) in the peripheral blood or bone marrow. Diagnosis of chronic myeloid leukemia (CML) requires the presence of the Philadelphia chromosome (a genetic mutation that results in the oncogenic BCR::ABL1 fusion gene).

Tyrosine kinase inhibitors are paramount in treatment, often used in combination with chemotherapy. Allogeneic stem cell transplant must follow due to rapid relapse.

Blast crisis refers to the transformation of chronic myeloid leukemia (CML) from the chronic or accelerated phase to blast phase.

The blast phase of CML is diagnosed by the percentage of blast cells in the peripheral blood or bone marrow, or the presence of an extramedullary accumulation of blast cells, or large foci or clusters of blasts in the bone marrow biopsy.[1]Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. [Erratum in: Blood. 2016 Jul 21;128(3):462.] https://ashpublications.org/blood/article/127/20/2391/35255/The-2016-revision-to-the-World-Health-Organization http://www.ncbi.nlm.nih.gov/pubmed/27069254?tool=bestpractice.com [2]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication]. https://www.nccn.org/guidelines/category_1  

CML is defined by the presence of the Philadelphia chromosome.[3]Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93. https://onlinelibrary.wiley.com/doi/10.1111/bjh.16971 http://www.ncbi.nlm.nih.gov/pubmed/32734668?tool=bestpractice.com